Breaking News Updates for the Psychedelics Industry | Page 4 of 9

Psychedelics News

Breaking News

8 Dec 2023

Terran Biosciences Granted Four Patents for New Forms of Psychedelics

Terran’s new patents cover new psilocybin forms, orally active DMT, and 5-MeO-DMT, and novel forms of ibogaine derivative tabernanthalog....

By Jason Najum

Breaking News

30 Nov 2023

Cybin Reports Positive Topline Data from Phase 2 Study of Major Depressive Disorder

Potentially groundbreaking results as Cybin's Phase 2 Study of CYB003 in Major Depressive Disorder showed 79% of patients in remission after two 12mg doses....

By Microdose NewsDesk

Breaking News

31 Oct 2023

Cybin Announces Positive Phase 2 Data for Phase 2 Depression Trial

This morning we received interim results on Cybin’s Phase 2 trial using its CYB003 psilocybin compound for depression. And they did not disappoint....

By Jason Najum

Breaking News

26 Oct 2023

Breaking News: Beckley Waves Acquires Nue Life

In breaking news, Beckley Waves announces the acquisition of Nue Life....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

6 Sep 2023

PharmaTher Submits New Drug Application to the FDA

Will PharmaTher be the next company to get a psychedelic medicine to market?...

By Jason Najum

Breaking News

31 Aug 2023

Breaking News: Otsuka Pharmaceutical to Acquire Mindset Pharma

This morning we received news of Mindset Pharma being sold to a big pharma player, Otsuka Pharmaceutical....

By Microdose NewsDesk

Breaking News

28 Aug 2023

Breaking News: Cybin to Acquire Small Pharma

In big breaking news, Cybin has signed a deal to acquire Small Pharma, giving Cybin an advanced DMT trial....

By Microdose NewsDesk

Breaking News

16 Aug 2023

COMPASS Pathways Announces Capital Raise of Up to $285 Million

COMPASS Pathways has announced a capital raise of up to $285 million, the largest cash injection the industry has seen in quite some time....

By Microdose NewsDesk

Breaking News

10 Aug 2023

Christian Angermayer Gives Insight on Future of Atai’s Ketamine Program

Christain Angermayer gave some clarification on PCN-101, atai's ketamine program, hinting at new direction for the compound....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result